Accelerate New York Seed Fund

Cress Health focuses on creating innovative digital solutions aimed at improving mental wellness for both individuals and organizations. The company's healthcare platform allows users to track their daily emotions and connect with peers, facilitating the sharing of experiences. By providing personalized reports, Cress Health enables users to gain a deeper understanding of their mental health, fostering self-awareness and support within a community framework. Through these offerings, Cress Health seeks to disrupt traditional approaches to mental wellness, making it more accessible and engaging for users.

Fuell the unifying idea: to create an urban mobility solution for cities.which is the best application of electric powertrains. The founders combined their experience and competences to invent a new experience entirely focused in the urban rider's needs

Qunnect, LLC is a technology company based in Stony Brook, New York, specializing in the development of light-based modular devices designed for transmitting, storing, and receiving encrypted information. Founded in 2017 as a spin-off from the Quantum Information Technology group at Stony Brook University, Qunnect focuses on creating advanced quantum devices that leverage principles of quantum physics to facilitate ultra-secure networks. These devices ensure that any observation of data is detected by the sender or recipient, enhancing cybersecurity. The company's offerings include solutions in quantum computing, quantum sensors, quantum cryptography, and quantum networks, among others. By engineering novel quantum memories and sources, Qunnect aims to revolutionize information networks and quantum computing, contributing to the evolution of cybersecurity into real-time threat detection systems.

Goldilocks Therapeutics is a biotechnology company founded in 2018 and based in Bedford, New York. The company specializes in developing therapeutic treatments for acute kidney injury, polycystic kidney disease, and other kidney-related conditions. Goldilocks Therapeutics employs proprietary mesoscale nanoparticles to deliver therapeutic payloads specifically to the renal tubule epithelium. This targeted approach allows for sustained-release of treatments, enhancing the ability of healthcare providers to effectively manage and improve the health of patients with kidney disorders.

HashLynx Inc. designs and develops platform for trade matching and settlement in the capital markets. The company was founded in 2018 and is based in Middletown, New York.

Aspisafe Solutions is a medical device company that specializes in developing innovative feeding medical devices, including catheters, feeding tubes, and nasogastric tubes. The company’s flagship product is a nasogastric tube designed to prevent stomach reflux, thereby reducing the risk of aspiration and pneumonia in intubated patients. Utilizing proprietary balloon pressure technology, this device works harmoniously with the patient's anatomy to secure and maintain the intubation catheter comfortably. Aspisafe Solutions aims to address critical healthcare challenges associated with feeding and ventilation in vulnerable patient populations.

Toggle is a company based in the United States that specializes in robotics as a service (RaaS) for the construction industry, specifically focusing on the assembly of rebar cages for reinforced concrete. The company has developed two-arm robotic platforms and proprietary jig designs that enable the construction of rebar structures directly from computer blueprints, allowing for greater precision and efficiency in construction processes. By integrating industrial robotics and automation into traditional construction methods, Toggle aims to transform the way infrastructure and buildings are created, addressing the increasing complexity of modern construction projects.

TargaGenix Inc. is a biotechnology company based in Stony Brook, New York, founded in 2013. The company focuses on developing innovative compounds targeting drug-resistant tumors and cancer stem cells. Its lead product, SBT-1214, has demonstrated the ability to completely eliminate tumors in various preclinical models, including those for colon, pancreatic, prostate, breast, and lung cancers. SBT-1214 also effectively down-regulates gene expression associated with stemness, aiding in the elimination of cancer stem cells. The product features additional chemical modifications and a novel fatty-acid based nanoemulsion formulation, which enhance its pharmacokinetic and pharmacodynamic properties while reducing toxicity.

EpiVax Oncology Inc. specializes in developing precision cancer immunotherapies focused on mutanome-directed and neo-epitope personalized treatments. Founded in 2017 and based in New York, the company offers advanced immuno-oncology solutions and neoantigen discovery services. Its research and development platform utilizes proprietary in-silico predictive algorithms to select optimal neo-epitopes, allowing clients to tackle unmet medical needs in cancer treatment that existing therapies do not adequately address.

Playback Health, Inc. specializes in creating patient engagement technology aimed at enhancing communication between healthcare practitioners and patients. Based in Mount Kisco, New York, the company's platform allows healthcare providers to design, develop, and share personalized multimedia content, including screen-capture videos, audio messages, and digital documents. This technology is intended to inform and educate patients about their specific diagnoses, treatment options, and discharge procedures. By providing a comprehensive view of the patient's healthcare journey, Playback Health enables patients to share their medical information with family, friends, and care professionals, fostering a collaborative care environment. The platform also integrates with existing healthcare systems to improve the delivery of medical information and instructions, thereby enhancing patient experience and engagement.

Concarlo Holdings, LLC focuses on developing solutions for drug-resistant breast cancer. Its technologies, including IpY, a cdk inhibitor, as well as ApY, an antibody focus on increasing drug efficacy and diagnostic evaluations for ER/PR+ Her 2- patients. The company was incorporated in 2010 and is headquartered in Brooklyn, New York.

Frenzy Labs, Inc. is a technology company that specializes in developing a visual search application platform to enhance image monetization for websites. Founded in 2017 and based in Marina Del Rey, California, Frenzy utilizes deep learning algorithms and computer vision to analyze website images, accurately identifying brands and products even in complex visual scenes without logos. The company offers various solutions, including self-labeling image technology that significantly reduces the need for manual labeling, thereby improving efficiency in managing image datasets. Frenzy's products include Fetch, a content monetization plugin tailored for fashion bloggers, and Frenzy Enterprise Solutions, which provides automated catalog management and precise image search capabilities for e-commerce platforms. By enabling users to seamlessly monetize their site images, Frenzy helps streamline the online shopping experience while minimizing the time and effort required to identify products.

Mirow LLC is a New York-based company that specializes in manufacturing smart mirrors for fitting rooms in the retail and hospitality sectors. Founded in 2016, Mirow's innovative mirrors enhance the shopping experience by offering features such as interactive touch screens, personalized recommendations, and the ability to request assistance or items in different sizes and colors. These smart mirrors also provide information on discounts and enable customers to engage with rewards programs. Mirow's solutions leverage AI-driven technology to improve service quality and generate valuable insights into customer behavior. The company has gained recognition in the industry, having been featured in notable publications, and serves a diverse clientele, including top-tier brands, while actively expanding its presence in both the US and European markets.

Digitouch Health is a United States-based company that develops a medical device aimed at monitoring hypertension and blood pressure. The device utilizes algorithm-enabled technology and oscillometry to measure blood pressure accurately without the need for calibration. It allows users to conveniently track their blood pressure levels and transmit readings directly to electronic health records, enhancing both personal health management and clinical oversight.

DepYmed, Inc. is a pharmaceutical company based in Cold Spring Harbor, New York, focused on developing therapeutics for breast cancer and rare diseases. Founded in 2014, the company specializes in phosphatase inhibition, particularly targeting protein tyrosine phosphatase 1B (PTP1B) as a potential treatment for HER2-positive breast cancer and Rett Syndrome. DepYmed's portfolio includes MSI-1436C (Trodusquemine), a potent PTP1B inhibitor, alongside a range of novel small molecules with copper-chelating properties, which may serve as therapeutic agents for conditions such as Wilson Disease and various cancers. The company is actively engaged in preclinical development of next-generation PTP1B inhibitors and selective copper chelators, collaborating with Cold Spring Harbor Laboratory to explore additional therapeutic indications.

Bioharmony Therapeutics, Inc. is engaged in the development of lysin-based antimicrobial therapeutics aimed at addressing multi-drug resistant Gram-negative bacterial infections. Established in 2016 and headquartered in New York, the company focuses on creating innovative treatments that target skin infections caused by multi-drug resistant Acinetobacter baumannii. These therapeutics utilize bacteriophages to effectively break down bacterial cell walls, which may also assist in treating more severe conditions such as hospital-acquired pneumonia and life-threatening blood or wound infections. Bioharmony Therapeutics is committed to providing solutions for patients facing challenging bacterial infections resistant to conventional antibiotics.

PainQx is a diagnostic/software company that has developed a next generation approach to objectively measure pain in humans. The PainQx platform achieves this by assessing neural activity from a patient’s brain and processing and decoding the data through proprietary algorithms. The output is a scaled pain and neurological side effects biomarker that is directly correlated to a patient’s pain state. The PainQx system is currently being used as a clinical assessment tool by companies using pain as a primary or secondary clinical end point to measure their drug’s and/or device’s efficacy.

Developer of genetic tests designed to identify young children at risk for autism. The company's genomic diagnostics is dedicated to developing precise genetic tests including its proprietary diagnostic device for detecting Copy Number Variation to identify at-risk children for autism as well as other genetic-based diseases that can be successfully treated through early clinical intervention and therapy, enabling patients to diagnose autism risk at an early age and access treatment and therapy for the same in a timely fashion.